Weekly Spotlight - 31.10.24

In the News

Comparing Rituximab and Cyclophosphamide for Childhood Vasculitis Treatment

In an effort to provide hope for families managing childhood ANCA-associated vasculitis, this study compares Rituximab (RTX) and Cyclophosphamide (CYC) in inducing remission for this serious paediatric condition. Conducted through the ARChiVe registry, researchers found that 63% of patients achieved remission with no significant difference between the two drugs, though hospitalisation rates were higher for Rituximab. While the study has limitations, including retrospective data and non-standardised treatment regimens, it highlights critical insights into the safety and effectiveness of these therapies, underscoring the need for more research to refine treatments for young patients.

ANCA Detection Methods in Vasculitis: A Comparative Study

This study focuses on ANCA detection in MPO-ANCA-associated vasculitis by comparing different immunoassays, including ELISA, CLEIA, FEIA, and LTIA, with immunofluorescence (IIF). Testing across 147 patients revealed strong performance from antigen-specific immunoassays, although combining these with IIF reduced diagnostic accuracy. Despite challenges in standardising measurements, the study highlights the promising role of antigen-specific immunoassays, which may help families feel supported by advancements in diagnostics, fostering community and optimism in managing vasculitis.

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!